Half-year report · HY
4483.TEDINET S100X27L
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥23.1bn | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥41.7bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥18.5bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥4.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥152.7bn | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥143.0bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥136.1bn | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥72.8bn | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥64.5bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥79.9bn | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥78.5bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥72.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥79.5bn | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥78.0bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥72.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥35.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥32.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥27.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥6.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥14.7bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥10.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥1.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥36.35 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥111.34 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.51 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥36 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥110.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.18 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.1% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 52.9% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥428m |
| Healthcare Big Datareportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥19.9bn |
| Healthcare Big Datareportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥19.9bn |
| Healthcare Big Datareportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.8bn |
| Tele Medicinereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Tele Medicinereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.2bn |
| Tele Medicinereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥23.1bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥6.0bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥401m |
| Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Tele Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Tele Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Tele Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥18.6bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥18.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 759
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 4516000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.0690 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 2976000 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0455 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 2666000 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0408 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 1876000 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0287 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 1051000 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0161 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 946000 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0145 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 937000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0143 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 565000 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0086 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 499000 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0076 | |
| Number of shares held | InterimInstant | 51491000 | |
| Shareholding ratio | InterimInstant | 0.7872 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 700 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 65380900 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 653809 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 25408 | |
| Number of shares issued shares voting rights | InterimInstant | 65407008 | |
| Number of voting rights issued shares voting rights | InterimInstant | 653809 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 700 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 700 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 700 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 700 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0000 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 32176000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 35863000000 | JPY |
| Trade and other receivables ca IFRS | Prior1YearInstant | 20065000000 | JPY |
| Trade and other receivables ca IFRS | InterimInstant | 16404000000 | JPY |
| Contract assets ca IFRS | Prior1YearInstant | 47000000 | JPY |
| Contract assets ca IFRS | InterimInstant | 2822000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 2063000000 | JPY |
| Other financial assets ca IFRS | InterimInstant | 1583000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 359000000 | JPY |
| Inventories ca IFRS | InterimInstant | 532000000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 1157000000 | JPY |
| Other current assets ca IFRS | InterimInstant | 1196000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |